BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental material
Ann Rheum Dis
Supplementary Table 3 . Persistent COVID-19 symptoms and other patient-reported outcomes in rheumatic disease patients following COVID-19 infection among those who did not receive any COVID- 19-specific therapy.
Non- breakthrough COVID-19
All rheumatic disease
Breakthrough COVID-19 infection (N=60)
p-value
patients (N=192)
infection (N=132)
Days to acute symptom resolution or date of survey if symptoms ongoing, median [IQR] CDC Definition of PASC (COVID-19 symptoms lasting at least 28 days post-COVID- 19 infection) WHO Definition of PASC (COVID-19 symptoms lasting at least 90 days post-COVID- 19 infection)*
25 (10, 92)
23 (8, 57)
28 (12, 200)
0.02
90 (47)
24 (40)
66 (50)
0.22
48 (32)
3 (8)
45 (40)
0.03
Pain (SF-MPQ) N
174
57
117
Median score [IQR]
5 (2, 10)
3 (1, 7)
6 (3, 11)
0.02
Pain rating index ordinal categories, n (%)
0.02
No pain
27 (14)
7 (12)
20 (15)
Mild pain
58 (30)
27 (45)
31 (23)
Discomforting, distressing, horrible, or excruciating pain
93 (48)
23 (38)
70 (53)
Fatigue (FSI) N
180
57
123
Median score [IQR]
49 (24, 80)
33 (13, 66)
54 (27, 84)
0.04
Functional status (mHAQ) N
184
57
127
Median score [IQR]
0.1 (0.0, 0.4)
0.1 (0.0, 0.4)
0.1 (0.0, 0.5)
0.25
Functional status categorical score, n (%)
0.07
Normal (<0.3)
117 (61)
42 (70)
75 (57)
Mild, moderate, or severe (0.3 to >1.8) Health status (SF-12) PCS-12 score, median [IQR]
67 (35)
15 (25)
52 (39)
42.7 (33.2, 51.7) 50.9 (39.3, 57.0)
45.5 (36.4, 54.0) 49.4 (39.6, 56.0)
41.1 (32.6, 50.3)
0.14
MCS-12 score, median [IQR]
51.3 (38.0, 57.6)
0.90
2022;0:1–9. doi: 10.1136/ard-2022-223439 Ann Rheum Dis , et al. Patel NJ
Powered by FlippingBook